Logan Capital Management Inc. Sells 54,557 Shares of Pfizer Inc. (NYSE:PFE)

Logan Capital Management Inc. trimmed its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 9.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 525,988 shares of the biopharmaceutical company's stock after selling 54,557 shares during the quarter. Logan Capital Management Inc.'s holdings in Pfizer were worth $13,954,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of PFE. Harbor Capital Advisors Inc. raised its holdings in Pfizer by 2.5% in the fourth quarter. Harbor Capital Advisors Inc. now owns 114,499 shares of the biopharmaceutical company's stock worth $3,038,000 after purchasing an additional 2,805 shares in the last quarter. Czech National Bank raised its stake in Pfizer by 6.4% in the fourth quarter. Czech National Bank now owns 1,228,716 shares of the biopharmaceutical company's stock valued at $32,598,000 after buying an additional 74,350 shares during the last quarter. Fiduciary Alliance LLC boosted its holdings in Pfizer by 15.5% in the fourth quarter. Fiduciary Alliance LLC now owns 9,803 shares of the biopharmaceutical company's stock worth $260,000 after acquiring an additional 1,319 shares in the last quarter. Kieckhefer Group LLC purchased a new position in shares of Pfizer in the 4th quarter valued at approximately $93,000. Finally, CHICAGO TRUST Co NA increased its position in shares of Pfizer by 11.8% in the 4th quarter. CHICAGO TRUST Co NA now owns 41,749 shares of the biopharmaceutical company's stock valued at $1,108,000 after acquiring an additional 4,400 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Trading Down 3.0%

NYSE PFE opened at $22.28 on Monday. The company's 50 day moving average price is $24.02 and its 200 day moving average price is $25.52. The firm has a market capitalization of $126.67 billion, a price-to-earnings ratio of 15.80, a PEG ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period last year, the firm earned $0.82 earnings per share. The company's revenue was down 7.8% on a year-over-year basis. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.72%. Pfizer's dividend payout ratio (DPR) is 124.64%.

Insider Activity

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.06% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on PFE shares. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target for the company. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, UBS Group increased their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.